Adjuvant pazopanib does not PROTECT against recurrence of high risk initially localised renal cell cancer, but does provide novel insights

Improved post-surgical management of the 70% of all renal cell cancer (RCC) patients who present to urological surgeons with initially localised RCC, to prevent subsequent progression, is an area of great need within uro-oncology.

Keywords

Carcinoma, Renal Cell, Humans, Indazoles, Kidney Neoplasms, Neoplasm Recurrence, Local, Nephrectomy, Pyrimidines, Sulfonamides

Journal Title

Journal of Clinical Oncology

Journal ISSN

0732-183X
1527-7755

Volume Title

35

Publisher

American Society of Clinical Oncology

Publisher DOI

https://doi.org/10.1200/JCO.2017.75.4242

Rights and licensing

Except where otherwised noted, this item's license is described as http://www.rioxx.net/licenses/all-rights-reserved

Sponsorship

GD Stewart has received educational grants from Pfizer and Intuitive Surgical; consultancy fees from Pfizer, EUSA Pharma and Cambridge Medical Robotics; Travel expenses from Pfizer and Speaker fees from Pfizer. RA Figlin has received research funding from Peloton, BMS, Argos Therapeutics, Exilexis, and Cerulean; consulting fees from Novartis, Pfizer, Nektar, Peloton, Calithera, and Acceleron. S Negrier reports honoraria from Pfizer, Novartis, EUSA Pharma, Ipsen Biotech and Bristol-Myers Squibb. BC Leibovich declares no conflicts of interest.

Collections

Scholarly Works - Surgery